Literature DB >> 28546874

Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of longitudinally extensive transverse myelitis caused by spinal dural arteriovenous fistula: case report and review of literature.

Michael A DiSano1, Russell Cerejo2, MaryAnn Mays3.   

Abstract

INTRODUCTION: The underlying causes of longitudinally extensive transverse myelitis (LETM) are broad and include inflammatory processes, compression and spinal dural arteriovenous fistula (SDAVF). Presenting symptoms of SDAVF are nonspecific and often go misdiagnosed. Acute clinical deterioration from SDAVF has been described following exertion or valsalva. However, deterioration has been recently recognized following steroid administration and may contribute to increased morbidity. CASE
PRESENTATION: We describe a 63-year-old woman with a 2-year history of intermittent lower extremity numbness and back pain, lumbar stenosis, who presented with subacute worsening of symptoms following a course of oral steroids for an upper respiratory infection. Initial whole-spine imaging was concerning for LETM and lumbar puncture was concerning for an inflammatory process. The patient was treated with intravenous (IV) methylprednisolone, after which she developed acute onset bilateral lower extremity paraparesis with a sensory level. Angiogram confirmed the diagnosis of SDAVF and the patient was treated surgically. Post-operative course was complicated and subsequent clinical improvement has been slow with incomplete recovery to date. DISCUSSION: This case illustrates the nonspecific presentation of SDAVF and the difficulty of differentiating it from other causes of LETM. It demonstrates acute clinical deterioration of SDAVF following steroid administration, a recently recognized clinical entity. The most likely mechanism is hydrostatic steroid effect coupled with iatrogenic fluid co-administration causing increased venous congestion. Previous cases have demonstrated this effect to be transient and resolves after discontinuation of steroids. This case highlights a recent association of increased morbidity following steroid administration despite definitive treatment.

Entities:  

Keywords:  Nervous system; Neurological manifestations; Spinal cord diseases

Year:  2017        PMID: 28546874      PMCID: PMC5436213          DOI: 10.1038/scsandc.2017.25

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  17 in total

1.  Acute paraparesis following intravenous steroid therapy in a case of dural spinal arteriovenous fistula.

Authors:  Macarena Cabrera; Carmen Paradas; Celedonio Márquez; Alejandro González
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

2.  Pearls & oy-sters: clues for spinal dural arteriovenous fistulae.

Authors:  A McKeon; E P Lindell; J L D Atkinson; B G Weinshenker; D G Piepgras; S J Pittock
Journal:  Neurology       Date:  2011-01-18       Impact factor: 9.910

3.  A unique presentation of a spinal dural arteriovenous fistula exacerbated by steroids.

Authors:  Roy E Strowd; Carol Geer; Alexander Powers; Nuhad Abou-Zeid
Journal:  J Clin Neurosci       Date:  2012-01-16       Impact factor: 1.961

Review 4.  Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder.

Authors:  K Jellema; C C Tijssen; J van Gijn
Journal:  Brain       Date:  2006-08-18       Impact factor: 13.501

5.  Reversible aggravation of neurological deficits after steroid medication in patients with venous congestive myelopathy caused by spinal arteriovenous malformation.

Authors:  C-S Lee; H W Pyun; E Y Chae; K-K Kim; S C Rhim; D C Suh
Journal:  Interv Neuroradiol       Date:  2009-11-04       Impact factor: 1.610

6.  [Can myelopathies secondary to arterio-venous dural fistulae be aggravated by intravenous corticosteroid therapy?].

Authors:  M E Söderlund; S Benisty; A Gaston; M Djindjian; P Cesaro; A Créange
Journal:  Rev Neurol (Paris)       Date:  2007-02       Impact factor: 2.607

7.  Multiple spinal dural arteriovenous fistulae and deterioration post lumbar puncture.

Authors:  A M Foote; S P C Bower; R A Danks; W Chong
Journal:  J Clin Neurosci       Date:  2009-10-27       Impact factor: 1.961

Review 8.  Spinal dural arteriovenous fistulas are not associated with prothrombotic factors.

Authors:  K Jellema; C C Tijssen; R Fijnheer; P G de Groot; P J Koudstaal; J van Gijn
Journal:  Stroke       Date:  2004-07-01       Impact factor: 7.914

9.  Treatment and outcome of spinal dural arteriovenous fistulas.

Authors:  U Schick; W Hassler
Journal:  Eur Spine J       Date:  2002-11-20       Impact factor: 3.134

10.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

View more
  3 in total

1.  Factors Associated with Rapidly Deteriorating Myelopathy in Patients with Spinal Arteriovenous Shunts.

Authors:  Takahiro Miyahara; Gohsuke Hattori; Hisaaki Uchikado; Yasuyuki Kaku; Yuki Ohmori; Kimihiko Orito; Yasuharu Takeuchi; Takayuki Kawano; Masaru Hirohata; Akitake Mukasa; Motohiro Morioka
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-11-12       Impact factor: 1.742

2.  Sudden-onset paraplegia in a 72-year-old male with a spinal dural arteriovenous fistula: illustrative case.

Authors:  Ikenna I Ogbu; Nikolaos Tzerakis; Zaineb Al-Shamary
Journal:  J Neurosurg Case Lessons       Date:  2021-08-30

3.  Imaging characteristics, misdiagnosis and microsurgical outcomes of patients with spinal dural arteriovenous fistula: a retrospective study of 32 patients.

Authors:  Han-Bing Zhang; Xiao-Lei Zhai; Lu Li; De-Shen Wu; Guang-Liang Zhuang; Qi-Wu Xu; Hui Guo; Jie Wang
Journal:  Ann Transl Med       Date:  2022-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.